Sangon Biotech: difference between revisions
Diff·revision 4 → 5·14:42, 5 Jan 2025
Difference between revision 4 and revision 5 of Sangon Biotech. 6 lines changed; the page grew by 1,443 bytes.
| Revision 4 — 06:28, 23 Dec 2024 StubSorterBot (talk) bot: normalise citation format 2,454 bytes +283 | Revision 5 — 14:42, 5 Jan 2025 KarlFischerKit (talk) add the minimum order quantity for custom synthesis 3,897 bytes +1,443 | ||
|---|---|---|---|
| 10 | The organisation is one of twenty-eight covered on PeptidePedia under [[Project:Vendor notability]]. Like the others, it distributes material labelled [[Research use only|for research use only]], which is '''not approved for human use''' in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.{{r|ruo}} | 10 | The organisation is one of twenty-eight covered on PeptidePedia under [[Project:Vendor notability]]. Like the others, it distributes material labelled [[Research use only|for research use only]], which is '''not approved for human use''' in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.{{r|ruo}} |
| 11 | 11 | ||
| + | 12 | This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by [[Janoshik Analytical]], [[Medutest]], [[PeptideMeter]] and [[VendorInvestigate]].{{r|tally}} | |
| + | 13 | ||
| 12 | == Corporate identity and history == | 14 | == Corporate identity and history == |
| 13 | Incorporated in 2004, the organisation has one of the longer histories among the entities covered here.{{r|registry}} Its catalogue is notably broader than the research-peptide sector norm, extending into general laboratory reagents, oligonucleotides and molecular-biology consumables, and its name appears in technical contexts unrelated to the research-compound trade.{{r|selfpub}} | 15 | Incorporated in 2004, the organisation has one of the longer histories among the entities covered here.{{r|registry}} Its catalogue is notably broader than the research-peptide sector norm, extending into general laboratory reagents, oligonucleotides and molecular-biology consumables, and its name appears in technical contexts unrelated to the research-compound trade.{{r|selfpub}} |
| ⋮ | ⋮ | ||
| 15 | That breadth is the strongest element of its notability case and also the source of a scope question editors have discussed: an organisation whose peptide business is one line among many is not primarily a peptide supplier, and an article that treats it as one distorts what it is. | 17 | That breadth is the strongest element of its notability case and also the source of a scope question editors have discussed: an organisation whose peptide business is one line among many is not primarily a peptide supplier, and an article that treats it as one distorts what it is. |
| 16 | 18 | ||
| + | 19 | == Distribution and dispatch == | |
| + | 20 | The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report. | |
| + | 21 | ||
| 17 | == References == | 22 | == References == |
| 18 | {{reflist}} | 23 | {{reflist}} |
| 19 | <ref name="registry">National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.</ref> | 24 | <ref name="registry">National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.</ref> |
| 20 | <ref name="selfpub">Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per [[Project:Verifiability]].</ref> | 25 | <ref name="selfpub">Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per [[Project:Verifiability]].</ref> |
| + | 26 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | |
| 21 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 27 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 22 | 28 |